Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

NCT04220866 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

DRUG: Ulevostinag
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC